Gaining experience with the NOACs

0Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

In this issue of Blood, Beyer-Westendorf et al analyzed the safety of long-term treatment with the novel oral anticoagulant (NOAC) factor Xa inhibitor, rivaroxaban, in a large registry of patients from their clinical practice with either venous thromboembolism (VTE) or atrial fibrillation. 1 During treatment, the annual major bleeding rate associated with rivaroxaban treatment was 3% to 4%, and did not differ between patients with VTE or atrial fibrillation. In addition, 60% of the major bleeding events were treated conservatively, by compression therapy or blood transfusion. Finally, the mortality rate due to bleeding after 90 days of treatment was 6.3%. All together, this study provides valuable data on the safety of rivoraxaban. Valuable, because most data on the safety of NOACs come from the phase 3 trials and not from clinical practice. © 2014 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Kamphuisen, P. W. (2014, August 7). Gaining experience with the NOACs. Blood. American Society of Hematology. https://doi.org/10.1182/blood-2014-06-578948

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free